New oral drug aims to treat anemia in dialysis patients
NCT ID NCT03461146
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 3 study tested an oral drug called MT-6548 (vadadustat) in 24 adults on hemodialysis in Japan who have anemia due to chronic kidney disease. The goal was to see if the drug can raise and keep hemoglobin levels in a healthy range. Participants took the pill and had their blood levels checked regularly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA; HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research site
Aichi, Japan
-
Research site
Chiba, Japan
-
Research site
Fukushima, Japan
-
Research site
Gunma, Japan
-
Research site
Hokkaido, Japan
-
Research site
Hyōgo, Japan
-
Research site
Ibaraki, Japan
-
Research site
Kagoshima, Japan
-
Research site
Nagano, Japan
-
Research site
Okayama, Japan
-
Research site
Okinawa, Japan
-
Research site
Osaka, Japan
-
Research site
Saitama, Japan
-
Research site
Shiga, Japan
-
Research site
Shizuoka, Japan
-
Research site
Yamagata, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vadadustat (MT-6548)
What this could lead to
If successful, this could provide a new oral treatment option for anemia in people on hemodialysis, reducing the need for injections.
What could go wrong
This is a small, early-phase trial with only 24 participants in Japan, so results may not apply broadly. The drug may not effectively maintain hemoglobin levels or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.